

North America Cancer Diagnostics Market Analysis, Companies Profiles, Size, Share, Growth, Trends and Forecast to 2024

https://marketpublishers.com/r/NB1DE7B7320EN.html

Date: October 2017

Pages: 150

Price: US\$ 2,500.00 (Single User License)

ID: NB1DE7B7320EN

Abstracts

In this region, North America cancer diagnostics is projected to reach USD 17.72 billion by 2024 from USD 7.59 billion in 2016, at a CAGR of 11.2% in the forecast period 2017 to 2024.

The major factors driving the growth of this market are the technological advancement in the field of early detection of cancer and high investment in cancer research by North America. These factors increase the demand for cancer diagnostic products.

Based on geography, the North America cancer diagnostics market is segmented into 5 geographical regions, such as,

U.S.

Mexico

Canada

North America cancer diagnostics market competition by top players including

GE Healthcare is going to dominate the cancer diagnostics market, by imaging following with Siemens Healthcare GmbH along with others such as

Hologic Inc.



Becton, Dickinson & Company.

Thermo Fisher Scientific, Inc. is going to dominate the cancer diagnostics market, by platform based following with Illumina, Inc. along with others such as

Roche Diagnostics

Abbott Laboratories, Inc.

QIAGEN.

The North America cancer diagnostics market is segmented on the basis of technology, application and geography.

On the basis of technology, North America cancer diagnostics market is segmented into 2 types, namely platform based and instrument based. In 2017, the cancer diagnostics instrument based segment is expected to dominate the market with a share of 69.4%

Cancer diagnostics platform based market is segmented into polymerase chain reaction (PCR), in situ hybridization (ISH), immunohistochemistry (IHC), next generation sequencing (NGS), DNA microarrays, flow cytometry and others.

Cancer diagnostics instrument based market is segmented into imaging and biopsy. Imaging is further segmented into magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography- computed tomography (PET-CT), mammography and ultrasound.

On the basis of application, the market is segmented into lung cancer, breast cancer, colorectal cancer, melanoma and others.



Contents

1. INTRODUCTION

- 1.1. OBJECTIVES OF THE STUDY
- 1.2. MARKET DEFINITION
- 1.3. OVERVIEW OF NORTH AMERICA CANCER DIAGNOSTICS MARKET
- 1.4. CURRENCY AND PRICING
- 1.5. LIMITATION
- 1.6. MARKETS COVERED

2. MARKET SEGMENTATION

- 2.1. MARKETS COVERED
- 2.2. GEOGRAPHIC SCOPE
- 2.3. YEARS CONSIDERED FOR THE STUDY
- 2.4. CURRENCY AND PRICING
- 2.5. RESEARCH METHODOLOGY
- 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
- 2.7. SECONDARY SOURCES
- 2.8. ASSUMPTIONS

3. MARKET OVERVIEW

- 3.1. DRIVERS
- 3.1.1. GROWTH OF AGING POPULATION AND RISING PREVALENCE OF CANCER
- 3.1.2. GOVERNMENT INITIATIVES FOR FUNDING AND AWARENESS ABOUT CANCER
- 3.1.3. KEY PLAYERS FOCUSING ON STRATEGIC DECISIONS TO GAIN MARKET SHARE
 - 3.1.4. INCREASING PREVELANCE OF CANCER
- 3.2. RESTRAINTS
- 3.2.1. STRINGENT REULATIONS IMPOSED BY INTERNATIONAL AND LOCAL AUTHORITIES
- 3.2.2. SHORTAGE OF SKILLED AND TRAINED PROFESSIONALS
- 3.3. OPPORTUNITIES
- 3.3.1. NANOTECHNOLOGY: FORTHCOMING REVOLUTION IN CANCER DIAGNOSIS



- 3.3.2. ARTIFICIAL INTELLIGENCE AND THE IMMINENT HEALTH REVOLUTION
- 3.3.3. GROWING MEDICAL TOURISM IN ASIA
- 3.4. CHALLENGES
- 3.4.1. INCREASING RIVALRY AMONG THE COMPETITORS
- 3.4.2. POOR ACCESS TO CANCER DETECTION AND HIGH TREATMENT COCTS IN LOWER INCOME COUNTRIES

4. PREMIUM INSIGHTS

5. EXECUTIVE SUMMARY

6. NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY

- 6.1. OVERVIEW
- 6.2. PLATFORM BASED
 - 6.2.1. POLYMERASE CHAIN REACTION(PCR)
 - 6.2.2. IN SITU HYBRIDIZATION (ISH)
 - 6.2.3. IMMUNOHISTOCHEMISTRY(IHC)
 - 6.2.4. NEXT GENERATION SEQUENCING (NGS)
 - 6.2.5. DNA MICROARRAYS
 - 6.2.6. FLOW CYTOMETRY
- 6.3. INSTRUMENT BASED
 - 6.3.1. IMAGING
 - 6.3.1.1. MAGENTIC RESONANCE IMAGING (MRI)
 - 6.3.1.2. CT(COMPUTED TOMOGRAPHY)
- 6.3.1.3. POSITRON EMISSION TOMOGRAPHY- COMPUTED TOMOGRAPHY (PET-CT)
 - 6.3.1.4. MAMMOGRAPHY
 - **6.3.1.5. ULTRASOUND**
 - 6.3.2. BIOPSY

7. NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION

- 7.1. OVERVIEW
- 7.2. LUNG CANCER
- 7.3. BREAST CANCER
- 7.4. COLORECTAL CANCER
- 7.5. MELANOMA
- 7.6. OTHERS



8. NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

- 8.1. OVERVIEW
- 8.2. NORTH AMERICA CANCER DIAGNOSTICS MARKET
 - 8.2.1. U.S.CANCER DIAGNOSTICS MARKET
 - 8.2.2. CANADA CANCER DIAGNOSTICS MARKET
 - 8.2.3. MEXICO CANCER DIAGNOSTICS MARKET

9. NORTH AMERICA CANCER DIAGNOSTICS MARKET, COMPANY LANDSCAPE

- 9.1. COMPANY SHARE ANALYSIS: NORTH AMERICA CANCER DIAGNOSTICS IMAGING MARKET
- 9.2. COMPANY SHARE ANALYSIS: NORTH AMERICA CANCER DIAGNOSTICS PLATFORM BASED MARKET

10. COMPANY PROFILES

- 10.1. C. R. BARD, INC.
 - 10.1.1. COMPANY OVERVIEW
 - 10.1.2. REVENUE ANALYSIS
 - 10.1.3. PRODUCT PORTFOLIO
- 10.1.4. RECENT DEVELOPMENTS
- 10.2. ILLUMINA, INC.
 - 10.2.1. COMPANY OVERVIEW
 - 10.2.2. REVENUE ANALYSIS
 - 10.2.3. RECENT DEVELOPMENTS
 - 10.2.4. PRODUCT PORTFOLIO
- 10.3. QIAGEN
 - 10.3.1. COMPANY OVERVIEW
 - 10.3.2. REVENUE ANALYSIS
 - 10.3.3. RECENT DEVELOPMENTS
 - 10.3.4. PRODUCT PORTFOLIO
- **10.4. ABBOTT**
 - 10.4.1. COMPANY OVERVIEW
 - 10.4.2. REVENUE ANALYSIS
 - 10.4.3. RECENT DEVELOPMENTS
 - 10.4.4. PRODUCT PORTFOLIO
- 10.5. SIEMENS HEALTHCARE GMBH



- 10.5.1. COMPANY OVERVIEW
- 10.5.2. REVENUE ANALYSIS
- 10.5.3. RECENT DEVELOPMENTS
- 10.5.4. PRODUCT PORTFOLIO
- 10.6. AGILENT TECHNOLOGIES
- 10.6.1. COMPANY OVERVIEW
- 10.6.2. REVENUE ANALYSIS
- 10.6.3. PRODUCT PORTFOLIO
- 10.6.4. RECENT DEVELOPMENTS
- 10.7. THERMO FISHER SCIENTIFIC INC.
 - 10.7.1. COMPANY OVERVIEW
 - 10.7.2. REVENUE ANALYSIS
 - 10.7.3. PRODUCT PORTFOLIO
 - 10.7.4. RECENT DEVELOPMENTS
- 10.8. BECTON, DICKINSON AND COMPANY
 - 10.8.1. COMPANY OVERVIEW
 - 10.8.2. REVENUE ANALYSIS
 - 10.8.3. PRODUCT PORTFOLIO
 - 10.8.4. RECENT DEVELOPMENTS
- 10.9. GE HEALTHCARE
 - 10.9.1. COMPANY OVERVIEW
 - 10.9.2. REVENUE ANALYSIS
 - 10.9.3. PRODUCT PORTFOLIO
- 10.9.4. RECENT DEVELOPMENTS
- 10.10. F. HOFFMANN-LA ROCHE LTD
 - 10.10.1. COMPANY OVERVIEW
 - 10.10.2. REVENUE ANALYSIS
 - 10.10.3. PRODUCT PORTFOLIO
- 10.10.4. RECENT DEVELOPMENTS
- 10.11. HOLOGIC INC.
 - 10.11.1. COMPANY OVERVIEW
 - 10.11.2. REVENUE ANALYSIS
 - 10.11.3. RECENT DEVELOPMENTS
 - 10.11.4. PRODUCT PORTFOLIO
- 10.12. KONINKLIJHE PHILIPS N.V.
 - 10.12.1. COMPANY OVERVIEW
 - 10.12.2. REVENUE ANALYSIS
 - 10.12.3. PRODUCT PORTFOLIO
 - 10.12.4. RECENT DEVELOPMENTS



11. RELATED REPORTS



List Of Tables

LIST OF TABLES

TABLE 1 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION)

TABLE 2 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)

TABLE 3 NORTH AMERICA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 4 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 5 NORTH AMERICA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)

TABLE 6 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)

TABLE 7 U.S.CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)

TABLE 8 U.S. PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 9 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 10 U.S. INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)

TABLE 11 U.S. CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)

TABLE 12 CANADA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)

TABLE 13 CANADA PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 14 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 15 CANADA INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)

TABLE 16 CANADA CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)

TABLE 17 MEXICO CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY, 2015 – 2024 (USD MILLION)

TABLE 18 MEXICO PLATFORM BASED CANCER DIAGNOSTICS MARKET, BY



PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 19 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY PRODUCT TYPE, 2015 – 2024 (USD MILLION)

TABLE 20 MEXICO INSTRUMENT BASED CANCER DIAGNOSTICS MARKET, BY IMAGING TYPE, 2015 – 2024 (USD MILLION)

TABLE 21 MEXICO CANCER DIAGNOSTICS MARKET, BY APPLICATION 2015 – 2024 (USD MILLION)



List Of Figures

LIST OF FIGURES

FIGURE 1 NORTH AMERICA CANCER DIAGNOSTICS MARKET SNAPSHOT (2017) FIGURE 2 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY COUNTRY (2016)

FIGURE 3 NORTH AMERICA CANCER DIAGNOSTICS MARKET: BY COUNTRY (2017)

FIGURE 4 NORTH AMERICA CANCER DIAGNOSTICS MARKET BY COUNTRY (2016 & 2024)

FIGURE 5 NORTH AMERICA CANCER DIAGNOSTICS MARKET, BY TECHNOLOGY (2017 & 2024)



I would like to order

Product name: North America Cancer Diagnostics Market Analysis, Companies Profiles, Size, Share,

Growth, Trends and Forecast to 2024

Product link: https://marketpublishers.com/r/NB1DE7B7320EN.html

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

First name:

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/NB1DE7B7320EN.html

To pay by Wire Transfer, please, fill in your contact details in the form below:

Last name:	
Email:	
Company:	
Address:	
City:	
Zip code:	
Country:	
Tel:	
Fax:	
Your message:	
	**All fields are required
	Custumer signature

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at https://marketpublishers.com/docs/terms.html

To place an order via fax simply print this form, fill in the information below and fax the completed form to $+44\ 20\ 7900\ 3970$

